Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-03-04 Sale |
2025-03-04 4:43 pm |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
679 | $8.99 | $6,104 | 141,083 (Direct) |
View |
| 2025-03-04 Sale |
2025-03-04 4:21 pm |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
2,572 | $8.99 | $23,122 | 169,068 (Direct) |
View |
| 2025-01-29 Sale |
2025-01-31 4:17 pm |
Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director |
265 | $9.97 | $2,642 | 19,468 (Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 5:23 pm |
Intellia Therapeutics Inc. | NTLA | Dube Michael P VP, Chief Accounting Officer |
1,372 | $12.18 | $16,711 | 45,640 (Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 5:22 pm |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
7,074 | $12.18 | $86,161 | 74,497 (Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 5:20 pm |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
9,557 | $12.18 | $116,404 | 87,666 (Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 5:20 pm |
Intellia Therapeutics Inc. | NTLA | Hicks Derek EVP, Chief Business Officer |
6,502 | $12.18 | $79,194 | 59,878 (Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 5:19 pm |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
26,807 | $12.18 | $326,509 | 999,530 (Indirect Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 5:16 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
8,966 | $12.18 | $109,206 | 77,388 (Direct) |
View |
| 2025-01-02 Sale |
2025-01-06 4:16 pm |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
7,978 | $12.17 | $97,089 | 64,048 (Direct) |
View |
| 2024-10-02 Sale |
2024-10-04 5:29 pm |
Intellia Therapeutics Inc. | NTLA | Dube Michael P VP, Chief Accounting Officer |
2,012 | $19.01 | $38,248 | 47,012 (Direct) |
View |
| 2024-07-01 Sale |
2024-07-03 1:15 pm |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
405 | $22.93 | $9,287 | 71,470 (Direct) |
View |
| 2024-06-17 Sale |
2024-06-20 5:00 pm |
Intellia Therapeutics Inc. | NTLA | Verwiel Frank Director |
1,505 | $25 | $37,625 | 17,948 (Direct) |
View |
| 2024-03-04 Sale |
2024-03-05 4:10 pm |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
2,297 | $32.99 | $75,778 | 128,323 (Direct) |
View |
| 2024-03-04 Sale |
2024-03-05 4:10 pm |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
605 | $32.99 | $19,959 | 116,542 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-03-01 Option Award |
2025-03-04 4:43 pm |
N/A 2035-02-28 |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
77,714 | $0 | 141,083 (Direct) |
View |
| 2025-03-01 Option Award |
2025-03-04 4:41 pm |
N/A 2035-02-28 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
332,000 | $0 | 1,331,530 (Direct) |
View |
| 2025-03-01 Option Award |
2025-03-04 4:34 pm |
N/A 2035-02-28 |
Intellia Therapeutics Inc. | NTLA | Dulac Edward J III EVP, Chief Financial Officer |
114,629 | $0 | 180,953 (Direct) |
View |
| 2025-03-01 Option Award |
2025-03-04 4:28 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Dube Michael P VP, Chief Accounting Officer |
14,000 | $0 | 59,640 (Direct) |
View |
| 2025-03-01 Option Award |
2025-03-04 4:26 pm |
N/A 2035-02-28 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
104,914 | $0 | 192,580 (Direct) |
View |
| 2025-03-01 Option Award |
2025-03-04 4:24 pm |
N/A 2035-02-28 |
Intellia Therapeutics Inc. | NTLA | Schultes Birgit C EVP, Chief Scientific Officer |
91,314 | $0 | 158,929 (Direct) |
View |
| 2025-03-01 Option Award |
2025-03-04 4:21 pm |
N/A 2035-02-28 |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
97,143 | $0 | 169,068 (Direct) |
View |
Ownership |
2025-01-23 5:41 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Schultes Birgit C EVP, Chief Scientific Officer |
0 | $0 | 249,121 (Direct) |
View |
| 2025-01-01 Exercise |
2025-01-03 4:30 pm |
2025-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
3,189 | $0 | 97,223 (Direct) |
View |
| 2025-01-01 Exercise |
2025-01-03 4:30 pm |
2025-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
7,850 | $0 | 1,026,337 (Direct) |
View |
| 2025-01-01 Exercise |
2025-01-03 4:30 pm |
2025-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
3,500 | $0 | 86,354 (Direct) |
View |
| 2024-07-22 Option Award |
2024-07-24 4:17 pm |
N/A 2034-07-21 |
Intellia Therapeutics Inc. | NTLA | Dulac Edward J III EVP, Chief Financial Officer |
162,543 | $0 | 162,543 (Direct) |
View |
| 2024-07-01 Option Award |
2024-07-03 1:15 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Dube Michael P VP, PAO and Interim PFO |
17,801 | $0 | 49,024 (Direct) |
View |
| 2024-06-13 Option Award |
2024-06-17 5:14 pm |
N/A 2034-06-12 |
Intellia Therapeutics Inc. | NTLA | Goff Brian Director |
37,706 | $0 | 37,706 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-14 4:22 pm |
N/A 2034-06-11 |
Intellia Therapeutics Inc. | NTLA | Verwiel Frank Director |
19,252 | $0 | 30,968 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-14 4:21 pm |
N/A 2034-06-11 |
Intellia Therapeutics Inc. | NTLA | Keresty Georgia Director |
19,252 | $0 | 35,398 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-14 4:20 pm |
N/A 2034-06-11 |
Intellia Therapeutics Inc. | NTLA | GOODMAN JESSE Director |
19,252 | $0 | 30,968 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-14 4:19 pm |
N/A 2034-06-11 |
Intellia Therapeutics Inc. | NTLA | Cohen Fred E Director |
19,252 | $0 | 60,968 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-14 4:18 pm |
N/A 2034-06-11 |
Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director |
19,252 | $0 | 31,248 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-14 4:16 pm |
N/A 2034-06-11 |
Intellia Therapeutics Inc. | NTLA | CHASE WILLIAM J Director |
19,252 | $0 | 38,208 (Direct) |
View |
Ownership |
2024-04-22 4:10 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Dube Michael P Principal Accounting Officer |
0 | $0 | 31,223 (Direct) |
View |
| 2024-03-01 Option Award |
2024-03-05 4:10 pm |
N/A 2034-02-28 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
92,760 | $0 | 136,687 (Direct) |
View |
| 2024-03-01 Option Award |
2024-03-05 4:10 pm |
N/A 2034-02-28 |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
79,146 | $0 | 128,323 (Direct) |
View |
| 2024-03-01 Option Award |
2024-03-05 4:10 pm |
N/A 2034-02-28 |
Intellia Therapeutics Inc. | NTLA | Hicks Derek EVP, Chief Business Officer |
71,814 | $0 | 108,801 (Direct) |
View |
| 2024-03-01 Option Award |
2024-03-05 4:10 pm |
N/A 2034-02-28 |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
76,302 | $0 | 116,542 (Direct) |
View |
| 2024-03-01 Option Award |
2024-03-05 4:10 pm |
N/A 2034-02-28 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
277,515 | $0 | 1,182,416 (Direct) |
View |
| 2024-03-01 Option Award |
2024-03-05 4:10 pm |
N/A 2034-02-28 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
94,556 | $0 | 148,928 (Direct) |
View |